Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients

NCT01656343 · clinicaltrials.gov ↗

COMPLETED

Status

775

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Transplantation
Transplantation, Kidney

Interventions

DRUG: Calcineurin inhibitors (CNI)
DRUG: Belatacept

Sponsor

Bristol-Myers Squibb